In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $94.18, up 2.09% from its previous closing price of $92.25. In other words, the price has increased by $2.09 from its previous closing price. On the day, 0.97 million shares were traded. TMDX stock price reached its highest trading level at $95.155 during the session, while it also had its lowest trading level at $91.7.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 8.30. In the meantime, Its Debt-to-Equity ratio is 2.27 whereas as Long-Term Debt/Eq ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Khayal Tamer I sold 2,407 shares for $76.43 per share. The transaction valued at 183,967 led to the insider holds 36,042 shares of the business.
Gordon Stephen bought 5,942 shares of TMDX for $389,855 on Mar 04 ’25. On Jan 07 ’25, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,083 shares for $80.05 each. As a result, the insider received 86,694 and left with 20,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 3185911552 and an Enterprise Value of 3351958272. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 93.23, and their Forward P/E ratio for the next fiscal year is 41.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.21 while its Price-to-Book (P/B) ratio in mrq is 13.85. Its current Enterprise Value per Revenue stands at 7.592 whereas that against EBITDA is 58.545.
Stock Price History:
The Beta on a monthly basis for TMDX is 1.78, which has changed by 0.022806287 over the last 52 weeks, in comparison to a change of 0.07545352 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 27.77%, while the 200-Day Moving Average is calculated to be -8.38%.
Shares Statistics:
It appears that TMDX traded 1.23M shares on average per day over the past three months and 1189990 shares per day over the past ten days. A total of 33.62M shares are outstanding, with a floating share count of 32.58M. Insiders hold about 3.67% of the company’s shares, while institutions hold 109.17% stake in the company. Shares short for TMDX as of 1743379200 were 9475553 with a Short Ratio of 7.71, compared to 1740700800 on 9330007. Therefore, it implies a Short% of Shares Outstanding of 9475553 and a Short% of Float of 34.22.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
